Published in Clin Sarcoma Res on February 08, 2012
A proposed role for neutrophil extracellular traps in cancer immunoediting. Front Immunol (2013) 1.02
Can a Bayesian Belief Network Be Used to Estimate 1-year Survival in Patients With Bone Sarcomas? Clin Orthop Relat Res (2017) 0.95
Biomarkers in Ewing Sarcoma: The Promise and Challenge of Personalized Medicine. A Report from the Children's Oncology Group. Front Oncol (2013) 0.90
Ewing sarcoma cells secrete EWS/Fli-1 fusion mRNA via microvesicles. PLoS One (2013) 0.82
Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic Landscapes. Int J Mol Sci (2015) 0.82
Quantification of the heterogeneity of prognostic cellular biomarkers in ewing sarcoma using automated image and random survival forest analysis. PLoS One (2014) 0.76
Localized Ewing sarcoma of the tibia. Clin Sarcoma Res (2013) 0.76
Prognostic Value of SUVmax Measured by Pretreatment Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Ewing Sarcoma. PLoS One (2016) 0.76
IDH Mutation Analysis in Ewing Sarcoma Family Tumors. J Pathol Transl Med (2015) 0.75
Comparison of Latino and non-Latino patients with Ewing sarcoma. Pediatr Blood Cancer (2013) 0.75
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther (2001) 14.78
REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer (2005) 4.85
Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol (2000) 4.15
EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol (1998) 3.10
Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer (2011) 2.95
Extraskeletal Ewing's sarcoma. Cancer (1999) 2.08
Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol (2007) 1.77
Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol (2000) 1.77
Adults with Ewing's sarcoma/primitive neuroectodermal tumor: adverse effect of older age and primary extraosseous disease on outcome. Ann Surg (1999) 1.76
Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol (2005) 1.66
EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol (1999) 1.58
Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J Clin Oncol (1997) 1.56
Modelling prognostic factors in advanced pancreatic cancer. Br J Cancer (2008) 1.53
Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children's Oncology Group. Pediatr Blood Cancer (2008) 1.49
Prognostic factors for patients with sarcomas of the pelvic bones. Cancer (1998) 1.45
Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer (2009) 1.38
Analysis of prognostic factors in Ewing sarcoma using a population-based cancer registry. Cancer (2010) 1.33
Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma. Clin Cancer Res (2004) 1.28
Prognostic impact of P53 status in Ewing sarcoma. Cancer (2000) 1.27
Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis. J Surg Oncol (2003) 1.25
Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer (1997) 1.22
Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer (2001) 1.18
Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol (2006) 1.17
Adult soft tissue Ewing sarcoma or primitive neuroectodermal tumors: predictors of survival? Arch Surg (2003) 1.16
Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol (1998) 1.14
Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. Med Pediatr Oncol (1999) 1.13
Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer (2002) 1.13
A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study. Cancer Res (2008) 1.09
Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol (2009) 1.09
Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol (2007) 1.08
Definitive surgery and multiagent systemic therapy for patients with localized Ewing sarcoma family of tumors: local outcome and prognostic factors. Cancer (2005) 1.08
Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer (2000) 1.08
Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene (2004) 1.05
Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br J Cancer (1999) 1.05
Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chromosomes Cancer (1999) 1.04
Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest (2001) 1.02
1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene (2011) 1.02
Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer (2005) 1.01
Concentration of vascular endothelial growth factor (VEGF) in the serum of patients with malignant bone tumors. Med Pediatr Oncol (2001) 1.00
Novel markers of subclinical disease for Ewing family tumors from gene expression profiling. Clin Cancer Res (2007) 0.98
Acquisition of secondary structural chromosomal changes in pediatric ewing sarcoma is a probable prognostic factor for tumor response and clinical outcome. Cancer (2001) 0.96
Clinical significance of Vascular Endothelial Growth Factor-A expression in Ewing's sarcoma. Eur J Cancer (2006) 0.95
Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer (2001) 0.94
Short telomeres: a novel potential predictor of relapse in Ewing sarcoma. Clin Cancer Res (2007) 0.93
Long-term follow-up and prognostic factors in Ewing's sarcoma. A multivariate analysis of 116 patients from a single institution. Oncology (1998) 0.93
Radiation therapy for Ewing's sarcoma: results from Memorial Sloan-Kettering in the modern era. Int J Radiat Oncol Biol Phys (2005) 0.93
Management of high-grade bone sarcomas over two decades: the Norwegian Radium Hospital experience. Acta Oncol (2006) 0.92
Prognostic significance of serum LDH in Ewing's sarcoma of bone. Oncol Rep (1999) 0.92
Small round blue cell tumors in bone: prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors. Semin Diagn Pathol (1996) 0.92
Increased c-myc oncogene expression in Ewing's sarcoma: correlation with Ki67 proliferation index. Tumori (1999) 0.91
Establishing long-term survival and cure in young patients with Ewing's sarcoma. Br J Cancer (2004) 0.91
Proteomic identification of heat shock protein 27 as a differentiation and prognostic marker in neuroblastoma but not in Ewing's sarcoma. Virchows Arch (2007) 0.89
Tumour volume as a predictor of necrosis after chemotherapy in Ewing's sarcoma. J Bone Joint Surg Br (1999) 0.89
Aberrant expression of tumor suppressor proteins in the Ewing family of tumors. Arch Pathol Lab Med (2001) 0.88
Overexpression of papillomavirus binding factor in Ewing's sarcoma family of tumors conferring poor prognosis. Oncol Rep (2008) 0.87
Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics. Clin Cancer Res (2009) 0.86
Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. Pediatr Blood Cancer (2007) 0.85
Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors. J Clin Oncol (2003) 0.84
Non-metastatic Ewing's sarcoma: twenty years of experience suggests that surgery is a prime factor for successful multimodality therapy. Int J Oncol (1999) 0.84
Treatment results of the Ewing sarcoma of bone and prognostic factors. Pediatr Blood Cancer (2010) 0.83
Efficacy of combined surgery and irradiation for localized Ewings sarcoma family of tumors. Pediatr Blood Cancer (2004) 0.82
Metastatic Ewing sarcoma/PNET of bone at diagnosis: prognostic factors--a report from Saudi Arabia. Med Pediatr Oncol (2001) 0.82
Xg expression in Ewing's sarcoma is of prognostic value and contributes to tumor invasiveness. Cancer Res (2010) 0.82
The role of meta-analysis in cancer clinical trials. Int J Clin Oncol (2009) 0.80
The prognostic and therapeutic relevance of p27kip1 in Ewing's family tumors. Clin Cancer Res (2004) 0.80
Is neuro-ectodermal differentiation of Ewing's sarcoma of bone associated with an unfavourable prognosis? Eur J Cancer (1995) 0.80
Angiogenesis and Ewing sarcoma--relationship to pulmonary metastasis and survival. J Pediatr Surg (2006) 0.79
Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population. J Cancer Res Clin Oncol (2007) 0.79
Prognostic value of clinicopathologic characteristics including neuroectodermal differentiation in osseous Ewing's sarcoma family of tumors in children. Tumori (1999) 0.78
Prognostic factors in patients with localized Ewing's sarcoma: the effect on survival of actual received drug dose intensity and of histologic response to induction therapy. J Chemother (1997) 0.76
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol (2011) 5.73
Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J Pathol (2010) 1.91
Multiple osteochondromas: clinicopathological and genetic spectrum and suggestions for clinical management. Hered Cancer Clin Pract (2004) 1.38
Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression. J Pathol (2010) 1.22
MicroRNAs at the human 14q32 locus have prognostic significance in osteosarcoma. Orphanet J Rare Dis (2013) 1.13
A short-term in vivo model for giant cell tumor of bone. BMC Cancer (2011) 0.92
Dedifferentiated peripheral chondrosarcomas: regulation of EXT-downstream molecules and differentiation-related genes. Mod Pathol (2009) 0.91
Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis. Clin Sarcoma Res (2012) 0.91
Opening the archives for state of the art tumour genetic research: sample processing for array-CGH using decalcified, formalin-fixed, paraffin-embedded tissue-derived DNA samples. BMC Res Notes (2011) 0.89
The CXCR4-CXCL12 axis in Ewing sarcoma: promotion of tumor growth rather than metastatic disease. Clin Sarcoma Res (2012) 0.88
Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy. Clin Cancer Res (2013) 0.85
A ΔRaf1-ER-inducible oncogenic zebrafish liver cell model identifies hepatocellular carcinoma signatures. J Pathol (2011) 0.82
Interobserver reliability in the histopathological diagnosis of cartilaginous tumors in patients with multiple osteochondromas. Mod Pathol (2012) 0.82
Reclassification and subtyping of so-called malignant fibrous histiocytoma of bone: comparison with cytogenetic features. Clin Sarcoma Res (2011) 0.75
Phenol levels during intralesional curettage and local adjuvant treatment of benign and low-grade malignant bone tumours. Clin Sarcoma Res (2012) 0.75
Paratesticular desmoplastic small round cell tumour: an unusual tumour with an unusual fusion; cytogenetic and molecular genetic analysis combining RT-PCR and COBRA-FISH. Clin Sarcoma Res (2012) 0.75
Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol (2016) 0.75
The Journal of Pathology 2008 Jeremy Jass Prize for Research Excellence in Pathology. J Pathol (2009) 0.75